Apparently, according the comment below, The Journal of Rheumatology will correct their chart (read link). The commentator “PainFree” is to be congratulated. It shows the caliber of scientifically minded people following Bioelectronics in particular and PEMF in general.
PainFreeJanuary 19, 2016 at 6:31 pm (Edit) Thanks. I wrote to the journal and the author about this inconsistency. I heard back from the journal thanking me for pointing out the error and that the authors have asked for a correction to be published. Since the devices are currently under FDA review, it is important that the true level of efficacy does not get masked by careless typos. The FDA hasn’t been the leader that it should be in allowing new technology that reduces drug usage to reach the US market expeditiously. The UK, EU and Canada are well ahead of the US on this. Hopefully, it will be different this time.”
I also pledge to be more careful in my naming of blogs–It was not the Oxford study, but rather published by the Oxford Press. There is a study on the Actipatch Oxford University is conducting. It would be more honest for me to blame sloppy labeling than getting the two juxtaposed. I had no evil intent.
“PainFreeJanuary 19, 2016 at 6:49 pm (Edit) One other thing: your post has a misleading title – the study was not conducted at Oxford. It was conducted at the Univ. of Messina, Italy, not that it is any less important. The Rheumatology journal where the results appeared is published by the Oxford University Press.Independently, there is an on-going clinical study being run at the Oxford University on the efficacy of the actipatch device in reducing back pain (https://www.clinicaltrials.gov/ct2/show/NCT02601807?term=ActiPatch&rank=1). The study is not sponsored by the company (except for providing free devices) and is being run by Oxford on its own. In their write up of the study, the Oxford physicians say this: “…Low back pain is a major health problem and if effective this has major economic implications as the device is cheap and safe.” and that is something. We know the results from the Messina Osteoarthritis study and the writing is on the wall.”
At any rate, participating in the correction of a well known journal passes for a win in The Zombie World Order.
BIEL is due for some good news. As PainFree puts it:
“The FDA hasn’t been the leader that it should be in allowing new technology that reduces drug usage to reach the US market expeditiously.”
True that, PainFree, true that. The FDA needs to show they are more than just an obstacle to progress.
Thanks PainFree for the comments. Also, thanks to the good folks at Rheumatology for their pending correction.